A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop
{{output}}
Background. We report a patient who developed corneal epithelial disorder repeatedly after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost. Case Report... ...
